176 related articles for article (PubMed ID: 21702115)
1. Off-label prescribing explained. Why your doctor may recommend meds that aren't FDA-approved for your condition.
Johns Hopkins Med Lett Health After 50; 2011 Jun; 23(4):7. PubMed ID: 21702115
[No Abstract] [Full Text] [Related]
2. U.S. physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey.
Chen DT; Wynia MK; Moloney RM; Alexander GC
Pharmacoepidemiol Drug Saf; 2009 Nov; 18(11):1094-100. PubMed ID: 19697444
[TBL] [Abstract][Full Text] [Related]
3. Intended and unintended consequences of the gabapentin off-label marketing lawsuit among patients with bipolar disorder.
Chace MJ; Zhang F; Fullerton CA; Huskamp HA; Gilden D; Soumerai SB
J Clin Psychiatry; 2012 Nov; 73(11):1388-94. PubMed ID: 23146199
[TBL] [Abstract][Full Text] [Related]
4. Gabapentin and Pregabalin for Pain - Is Increased Prescribing a Cause for Concern?
Goodman CW; Brett AS
N Engl J Med; 2017 Aug; 377(5):411-414. PubMed ID: 28767350
[No Abstract] [Full Text] [Related]
5. Outcome reporting in industry-sponsored trials of gabapentin for off-label use.
Vedula SS; Bero L; Scherer RW; Dickersin K
N Engl J Med; 2009 Nov; 361(20):1963-71. PubMed ID: 19907043
[TBL] [Abstract][Full Text] [Related]
6. Examination of the evidence for off-label use of gabapentin.
Mack A
J Manag Care Pharm; 2003; 9(6):559-68. PubMed ID: 14664664
[TBL] [Abstract][Full Text] [Related]
7. Staying on track when prescribing off-label.
Fitzgerald AS; O'Malley PG
Am Fam Physician; 2014 Jan; 89(1):4-5. PubMed ID: 24444499
[No Abstract] [Full Text] [Related]
8. Off-label prescribing among office-based physicians.
Radley DC; Finkelstein SN; Stafford RS
Arch Intern Med; 2006 May; 166(9):1021-6. PubMed ID: 16682577
[TBL] [Abstract][Full Text] [Related]
9. Patterns of prescribing antiepileptic drugs for bipolar disorder.
Kish-Doto J; Evans WD; Squire C; Williams P; Ranney LM; Melvin CL
J Psychiatr Pract; 2008 Mar; 14 Suppl 1():35-43. PubMed ID: 19034208
[TBL] [Abstract][Full Text] [Related]
10. Off-label drugs: question your doctor.
Consum Rep; 2007 Jun; 72(6):47. PubMed ID: 17632948
[No Abstract] [Full Text] [Related]
11. False Claims Act prosecution did not deter off-label drug use in the case of neurontin.
Kesselheim AS; Darby D; Studdert DM; Glynn R; Levin R; Avorn J
Health Aff (Millwood); 2011 Dec; 30(12):2318-27. PubMed ID: 22147859
[TBL] [Abstract][Full Text] [Related]
12. Dicing with death : there's a good chance that the pills your doctor prescribed will do you no good and might even harm you.
Muir H
New Sci; 2006 Jul 29-Aug 4; 191(2562):38-41. PubMed ID: 17115486
[No Abstract] [Full Text] [Related]
13. FDA approves gabapentin prodrug as restless legs treatment.
Thompson CA
Am J Health Syst Pharm; 2011 May; 68(10):862. PubMed ID: 21546634
[No Abstract] [Full Text] [Related]
14. Off-label prescribing patterns of antidepressants in children and adolescents.
Lee E; Teschemaker AR; Johann-Liang R; Bazemore G; Yoon M; Shim KS; Daniel M; Pittman J; Wutoh AK
Pharmacoepidemiol Drug Saf; 2012 Feb; 21(2):137-44. PubMed ID: 21538674
[TBL] [Abstract][Full Text] [Related]
15. Are "off-labels" legal?
Price EC
Mich Health Hosp; 1998; 34(6):20-1. PubMed ID: 10187136
[TBL] [Abstract][Full Text] [Related]
16. Off-label antidepressant use in children and adolescents compared with young adults: extent and level of evidence.
Czaja AS; Valuck R
Pharmacoepidemiol Drug Saf; 2012 Sep; 21(9):997-1004. PubMed ID: 22760843
[TBL] [Abstract][Full Text] [Related]
17. Off-label prescribing of medications for pain: maintaining optimal care at an intersection of law, public policy, and ethics.
Ruble J
J Pain Palliat Care Pharmacother; 2012 Jun; 26(2):146-52. PubMed ID: 22764854
[TBL] [Abstract][Full Text] [Related]
18. Be wary of recommending off-label use of meds.
Luttrull S
Adv Nurse Pract; 2001 Feb; 9(2):18. PubMed ID: 12416047
[No Abstract] [Full Text] [Related]
19. Off-label medication use in adult critical care patients.
Lat I; Micek S; Janzen J; Cohen H; Olsen K; Haas C
J Crit Care; 2011 Feb; 26(1):89-94. PubMed ID: 20716478
[TBL] [Abstract][Full Text] [Related]
20. Persistent use of against-label statin-fibrate combinations from 2003-2009 despite United States Food and Drug Administration dose restrictions.
Alford JC; Saseen JJ; Allen RR; Nair KV
Pharmacotherapy; 2012 Jul; 32(7):623-30. PubMed ID: 22570173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
